Holen Sie sich die Stockscreener-App
13.45
2.96%
-0.41
Handel nachbörslich:
13.45
Schlusskurs vom Vortag:
$13.86
Offen:
$13.92
24-Stunden-Volumen:
508.03K
Relative Volume:
1.00
Marktkapitalisierung:
$783.16M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-153.16M
KGV:
-3.9911
EPS:
-3.37
Netto-Cashflow:
$-134.48M
1W Leistung:
-22.12%
1M Leistung:
-19.80%
6M Leistung:
-41.95%
1J Leistung:
+52.84%
1-Tages-Spanne:
$13.14
$14.14
1-Wochen-Bereich:
$13.14
$17.50
52-Wochen-Spanne:
$7.64
$30.19
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Firmenname
Cullinan Therapeutics Inc
Sektor
Branche
Telefon
617-410-4650
Adresse
ONE MAIN STREET, CAMBRIDGE
Vergleichen Sie CGEM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| CGEM | 13.45 | 783.16M | 0 | -153.16M | -134.48M | -3.37 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-01 | Eingeleitet | Stifel | Buy |
| 2024-04-15 | Eingeleitet | William Blair | Outperform |
| 2024-02-15 | Eingeleitet | Wedbush | Outperform |
| 2023-06-15 | Eingeleitet | TD Cowen | Outperform |
| 2022-11-21 | Eingeleitet | BTIG Research | Buy |
| 2021-04-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | Eingeleitet | Evercore ISI | Outperform |
| 2021-02-02 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-02-02 | Eingeleitet | SVB Leerink | Outperform |
| 2021-02-01 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cullinan Therapeutics Inc Aktie (CGEM) Neueste Nachrichten
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 6.3%Time to Sell? - MarketBeat
Blue Owl Capital Holdings LP Adjusts Stake in Cullinan Therapeutics Inc - GuruFocus.com
Cullinan advances lupus treatment with new clinical trial By Investing.com - Investing.com Canada
Cullinan advances lupus treatment with new clinical trial - Investing.com
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 - GlobeNewswire
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager - The Bakersfield Californian
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 - GlobeNewswire Inc.
Cullinan Therapeutics' chief scientific officer sells $125,120 in stock By Investing.com - Investing.com Australia
Cullinan Therapeutics' chief scientific officer sells $125,120 in stock - Investing.com India
Cullinan Therapeutics: Q3 Earnings Snapshot - Darien Times
Insider Sale: Chief Scientific Officer of Cullinan Therapeutics Inc (CGEM) Sells Shares - GuruFocus.com
Cullinan Therapeutics Inc (CGEM) Quarterly 10-Q Report - Quartzy
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - GlobeNewswire
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference - StockTitan
Vanguard Group Inc's Strategic Acquisition in Cullinan Therapeutics Inc - GuruFocus.com
Cullinan Therapeutics to Present Preclinical Data for - GlobeNewswire
Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024 - StockTitan
Analysts Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Target Price at $31.67 - MarketBeat
FY2027 Earnings Forecast for CGEM Issued By Leerink Partnrs - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Receives New Coverage from Analysts at UBS Group - MarketBeat
Exchange Traded Concepts LLC Sells 2,961 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
SG Americas Securities LLC Sells 70,115 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
cullinan oncology, inc. Earnings dates - RTTNews
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 3.2%Here's Why - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Short Interest Update - MarketBeat
Cullinan Oncology stock gets 5% price target increase, H.C. Wainwright remains bullish after FDA approval - Investing.com
Cullinan Therapeutics (NASDAQ:CGEM) Trading Up 7%Here's Why - MarketBeat
Cullinan Therapeutics' (CGEM) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Cullinan Therapeutics Gets FDA Approval for Lupus Treatment Study - Marketscreener.com
Cullinan Therapeutics Receives U.S. FDA Clearance of - GlobeNewswire
Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus - StockTitan
How did Cullinan Therapeutics Inc (CGEM) fare last session? - US Post News
Cullinan Therapeutics Inc [CGEM] Records 200-Day SMA of $17.94 - Knox Daily
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Algert Global LLC Reduces Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
The Potential Rise in the Price of Cullinan Therapeutics Inc (CGEM) following insiders activity - Knox Daily
Metric Deep Dive: Understanding Cullinan Therapeutics Inc (CGEM) Through its Ratios - The Dwinnex
Results from Cullinan Therapeutics Inc (CGEM) show potential - US Post News
Perceptive Advisors LLC Takes Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Sold by Blue Owl Capital Holdings LP - MarketBeat
Lynx1 Capital Management LP Buys New Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
There is no doubt that Cullinan Therapeutics Inc (CGEM) ticks all the boxes. - SETE News
Deerfield Management Company L.P. Series C Increases Stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Cullinan Therapeutics Inc (CGEM)’s stock price in review: A technical analysis - US Post News
Quarterly Metrics: Quick and Current Ratios for Cullinan Therapeutics Inc (CGEM) - The Dwinnex
CGEM’s Debt-to-Equity Ratio at 0.00: What It Means for Cullinan Therapeutics Inc’s Future - The InvestChronicle
Paradigm Capital Management Inc. NY Has $39.46 Million Stock Holdings in Concentrix Co. (NASDAQ:CNXC) - MarketBeat
Rhumbline Advisers Raises Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Highlights of Current Entertainment News - Devdiscourse
Four Tri-City actors cast in Willy Wonka's wacky chocolate world - The Tri-City News
Transgender Singer Xavian Wu's Journey, China's Micro Dramas, and Meryl Streep's UN Solidarity - Devdiscourse
Finanzdaten der Cullinan Therapeutics Inc-Aktie (CGEM)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):